A new study outlines and defines sex differences in outcomes of tailored Alzheimer's disease clinical interventions.
15 newly discovered "hotspots" in the genome that either speed up or slow down brain aging could be new targets for the development of Alzheimer's medications and therapies for other brain disorders.
Carriers of the Alzheimer's associated APOE4 gene have more than double the risk of developing severe COVID-19, a new study reports. Additionally, more microscopic hemorrhages were found in the brains of APOE4 carriers who contracted coronavirus. Researchers report those with the APOE4 gene also are more susceptible to developing long-term symptoms following COVID infection, including an increased risk of mental fatigue.
A new framework reveals Alzheimer's disease is far more complex than previously believed. Rather than being a disease where the same causes produce the same outcomes, researchers found three different models for the disease, each with its own characterizations and dynamics.
Dasatinib, an FDA-approved drug for chronic myeloid leukemia, and an experimental drug for liver cancer reduced neuroinflammation, tau phosphorylation, and amyloid secretion in cell cultures of post-mortem brain samples of those with the APOE4 Alzheimer's associated gene.
Inhibiting the NHE6 gene abolished the formation of amyloid-beta plaques in mouse models of Alzheimer's disease.
Bumetanide, an FDA-approved potent diuretic used to treat fluid retention caused by heart, kidney, and liver disease may lower the risk of developing Alzheimer's disease for those with a genetic predisposition.
Stem cell study reveals astrocytes carrying the Alzheimer's associated APOE4 gene release more cholesterol than those carrying the APOE3 gene. Findings shed light on how different versions of the APOE gene in astrocytes influence amyloid-beta production and how the oversupply of cholesterol associated with APOE4 astrocytes may promote amyloid-beta formation in Alzheimer's patients.
Subtle changes in fractal motor activity regulation in cognitively healthy women may be a sign of preclinical Alzheimer's disease, researchers report.